ABSI

Absci Corporation NMS · ABSI

$8.24 -0.07 (-0.90%)

Pullback · -1.14σ

+ Compare Open in Sniper

Mkt cap $1.4B

P/E —

Day $8.10 – $8.37

52wk $2.24 – $12.06

Avg vol 6.0M

Beta 2.33

Div yld —

Next earnings 2026-08-11

Quick read

At a glance

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.

ABSI last traded at $8.24, down 0.9% on the day; that's in the middle part of its 52-week range ($2.24–$12.06). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

The next scheduled earnings report (2026-08-11) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — not meaningfully overheated yet.

Long —

Setup score 14 / 100

Price is stretched slightly below its normal range — a light stretch — early days, worth watching.

· KC1 lower stretch — light dip
· Counter-trend long in strong downtrend

Technical read: KC1 lower, -1.18 ATR from EMA21 · no notable pattern

What it means: Price is stretched slightly below its normal range — a light stretch — early days, worth watching. The trigger bar shows no standout candle signal yet.

Score split: chart signals 14 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 14 pts

Cycle position 14

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 16 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Aligned with strong downtrend (strong tailwind)

Technical read: below KC1 upper, -1.18 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 16 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Unknown Accounting: Weak

Fair-value range

$0.05 – $0.05

Accounting quality Weak

✓ More cash than debt
✓ Current ratio 6.57 (antifragile)
✓ Debt/equity 0.14 (antifragile)

⚠ Negative retained earnings
⚠ Stock comp 654% of revenue (heavy dilution)

Key statistics

All statistics →

ABSI is a $1.4 billion company, it moves harder than the market (beta 2.3).

Market cap $1.4B

P/E ttm —

Beta 2.33

52w range $2.24 – $12.06

Avg volume 6.0M

Dividend yield —

Sector Healthcare

Next earnings 2026-08-11

52-week range · today's price

$2.24$12.06

More on ABSI

Options idea

See more →

CALL $9 2026-08-21

$0.90

PUT $9 2026-08-21

$1.60

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.19 / -0.20
Surprise: +4.6%
Next report: 2026-08-11

About

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopec…